They validated their hypothesis by depleting CD8+ T cells in NASH mice without liver cancer and found that CD8+PD1+ T cells not only had defected immune surveillance but were also able to promote HCC development in a NASH background. The gene discussed is CD8A; the disease is metabolic dysfunction-associated steatohepatitis.